Skip to NavigationSkip to content

AZ drug gets orphan status for rare inflammatory disease

Published on 09/03/16 at 09:12am

AstraZeneca’s biologics R&D arm MedImmune has been granted Orphan Drug Designation by the FDA for its investigational anti-CD19 monoclonal antibody, MEDI-551, for the treatment of patients with neuromyelitis optica (NMO) as well as neuromyelitis optica spectrum disorders (NMOSD).

MEDI-551 is currently in Phase IIb clinical development for NMO (also known as Devic’s syndrome): a rare and potentially fatal autoimmune disease of the central nervous system in which the immune system attacks healthy cells, most commonly in the optic nerves and spinal cord, resulting in severe damage. NMO causes severe muscle weakness and paralysis, loss of vision, respiratory failure, problems with bowel and bladder function and neuropathic pain.

Research has shown that patients with NMO and NMOSD develop antibodies against a protein in their body called aquaporin-4, and these antibodies play a key role in NMO disease pathogenesis. MEDI-551 directly targets and depletes cells that produce these antibodies.

MEDI-551 is currently being evaluated in a global clinical trial in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders, and is also being studied in a Phase II trial in diffuse B-cell lymphoma.

If eventually approved, MEDI-551 would be the first drug to have been so for NMO, which affects about five in 100,000 people. The FDA grants orphan drug status to promising new medicines for conditions which affect fewer than 200,000 people in the US.

Bing Yao, senior vice president, R&D and head of the Respiratory, Inflammation and Autoimmunity Innovative Medicines unit, MedImmune, says: “The orphan designation for MEDI-551 underscores the significant need for an effective medicine for NMO, a rare, devastating disease which causes increasing damage and disability with each attack. MEDI-551 has a unique, targeted mechanism of action offering potential for the treatment of NMO. We look forward to working with the FDA to advance MEDI-551 to patients suffering from NMO as quickly as possible.”

Joel Levy

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches